Organon's Q1 2025 earnings report showed significant declines across key financial metrics, leading to a drastic 30% drop in share price following a >90% dividend cut. The company's revenue ...

Shares of NYSE OGN opened at $9.60 on Friday. Organon & Co. has a twelve month low of $9.18 and a twelve month high of $23.10. The company has a 50 day moving average of $13.46 and a 200 day ...

Organon currently expects that it will record approximately $6 million of milestone expense in the first quarter of 2025. Organon does not forecast IPR&D (in process research and development) or ...

Organon, a women’s health-focused pharma company based in Jersey City, expects to eliminate 93 jobs as part of an effort to optimize internal operations. In a filing with the state Department of ...

This Women’s Month, Organon, dedicated to advancing women’s health at every stage of life, is raising awareness on the preventability and treatability of heart disease, urging women to take ...

Organon does not currently expect to record any milestone expense in the fourth quarter of 2024. Organon’s fourth quarter and full year 2024 results have not been finalized and are subject to ...

Organon Philippines, a women’s health company, recently unveiled its Her Health Finder, an online tool that aims to empower women to take control of their health by providing quick, easy access ...

Please provide your email address to receive an email when new articles are posted on . Organon is an independent global health care company dedicated to promoting women’s health. Organon will ...

Organon is broadening its presence in dermatology with a deal to acquire Dermavant, a company whose main asset is a commercialized plaque psoriasis drug that could soon expand its approval to ...